ArticleToxins2025
Topography of the Corrugator Supercilii Muscle Relative to the Eyebrow and Its Clinical Application in Botulinum Toxin Injections.
Article in Toxins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The purpose of this study was to elucidate the topography of the corrugator supercilii muscle (CSM) relative to the eyebrow with the aim of providing topographical guidance for botulinum toxin type A (BTX-A) injections in the East Asian population. Thirty-six hemifaces of 18 donated bodies for anatomical studies were dissected. Prior to dissection, four specific points on the eyebrow were marked to serve as reference points. A superimposition method for analyzing the position of the CSM relative to the eyebrow involved overlaying an image showing the dissected muscle onto a pre-existing image that contained reference lines indicating the eyebrow landmarks. The CSM almost overlaps the eyebrow at its medial end. Significantly, the central part of the CSM's width was positioned just above the upper point of the eyebrow, being closely aligned with the midpupillary line. There was minimal overlap of the CSM beyond the midpupillary line on the lateral side, indicating that this muscle becomes relatively scarce or less distinct as it extends laterally from the midpupillary line. For effectively targeting the CSM, it is recommended to inject BTX-A precisely at the center of the medial end of the eyebrow just above the midpupillary line.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.